Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/111833
Título: | Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies | Autor: | Kumar, Mahesh Virmani, Tarun Kumar, Girish Deshmukh, Rohitas Sharma, Ashwani Duarte, Sofia Brandão, Pedro Fonte, Pedro |
Palavras-chave: | tuberculosis; ligand; nanoformulation; nanoparticle; patent; mannose; folic acid | Data: | 26-Set-2023 | Editora: | MDPI | Projeto: | This research was funded by Fundação para a Ciência e a Tecnologia (FCT) in the scope of the projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020 of the Research Unit Center for Marine Sciences—CCMAR; UIDB/04565/2020 and UIDP/04565/2020 of the Research Unit Institute for Bioengineering and Biosciences—IBB; and LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bio-economy—4HB; and UIDB/04585/2020 of the Research Unit Egas Moniz Center for Interdisciplinary Research (CiiEM). | Título da revista, periódico, livro ou evento: | Pharmaceuticals | Volume: | 16 | Número: | 10 | Resumo: | The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. The rise of MDR strains endangers future TB control. Despite these concerns, the hunt for an efficient treatment continues. One breakthrough has been the use of nanotechnology in medicines, presenting a novel approach for TB treatment. Nanocarriers, such as lipid nanoparticles, nanosuspensions, liposomes, and polymeric micelles, facilitate targeted delivery of anti-TB drugs. The benefits of nanocarriers include reduced drug doses, fewer side effects, improved drug solubility, better bioavailability, and improved patient compliance, speeding up recovery. Additionally, nanocarriers can be made even more targeted by linking them with ligands such as mannose or hyaluronic acid. This review explores these innovative TB treatments, including studies on nanocarriers containing anti-TB drugs and related patents. | URI: | https://hdl.handle.net/10316/111833 | ISSN: | 1424-8247 | DOI: | 10.3390/ph16101360 | Direitos: | openAccess |
Aparece nas coleções: | FCTUC Química - Artigos em Revistas Internacionais I&D CQC - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Nanocarriers-in-Tuberculosis-Treatment-Challenges-and-Delivery-StrategiesPharmaceuticals.pdf | 6.9 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
25
Visto em 22/mai/2024
Downloads
25
Visto em 22/mai/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons